Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905247 | 0.82 | KCNN4 (0.38) | KCNN4CYP1A2ALDH1A1ALOX15CYP2C19 | |
| SCHEMBL9210109 | 0.78 | CYP2C19 (0.44) | KCNN4CYP1A2ALDH1A1ALOX15CYP2C19 | |
| SCHEMBL28006379 | 0.77 | MAPK1 (0.40) | KCNN4ALDH1A1ALOX15CYP2C19PTPN1 | |
| SCHEMBL183489 | 0.76 | KIF11 (0.40) | KCNN4CYP1A2ALDH1A1ALOX15CYP2C19 | |
| SCHEMBL11110723 | 0.74 | MAPK1 (0.36) | KCNN4CYP1A2ALDH1A1ALOX15CYP2C19 | |
| SCHEMBL9207734 | 0.74 | KCNN4 (0.36) | KCNN4CYP1A2ALDH1A1ALOX15CYP2C19 | |
| SCHEMBL135667 | 0.73 | MAPK1 (0.56) | KCNN4ALDH1A1ALOX15CYP2C19MAPK1 | |
| SCHEMBL131978 | 0.73 | MAPK1 (0.44) | KCNN4ALDH1A1ALOX15CYP2C19MAPK1 | |
| SCHEMBL1683185 | 0.73 | TSHR (0.44) | KCNN4CYP1A2ALDH1A1ALOX15PTPN1 | |
| SCHEMBL28380386 | 0.72 | MAPK1 (0.36) | KCNN4ALDH1A1ALOX15CYP2C19MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3808177-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Arbutus Biopharma Corporation (CA) | 2021-04-21 | — | — | EP | disclosed |
| US-10835612-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-11-17 | — | — | US | disclosed |
| EP-3238738-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2020-09-23 | — | — | EP | disclosed |
| US-20180125985-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-05-10 | — | — | US | disclosed |
| US-20180064807-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-03-08 | — | — | US | disclosed |
| EP-3238738-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Arbutus Biopharma Corporation (CA) | 2017-11-01 | — | — | EP | disclosed |
| EP-2355658-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2017-09-27 | — | — | EP | disclosed |
| US-9764036-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-09-19 | — | — | US | disclosed |
| US-20160213785-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-07-28 | — | — | US | disclosed |
| US-9220683-B2 | Lipids and compositions for the delivery of therapeutics | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2015-12-29 | — | — | US | disclosed |
| US-20120095075-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120027796-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2355658-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Alnylam Pharmaceuticals Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010054406-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125985-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | KCNN4 4854/4885CYP1A2 4761/4885ALDH1A1 3880/4885 |
| US-20160213785-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | KCNN4 4854/4885CYP1A2 4761/4885ALDH1A1 3880/4885 |
| US-20180064807-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | KCNN4 4857/4885CYP1A2 4721/4885ALDH1A1 3847/4885 |
| US-20120095075-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | KCNN4 4857/4885CYP1A2 4721/4885ALDH1A1 3847/4885 |
| US-10835612-B2 | Lipids and compositions for the delivery of therapeutics | CETP, LCAT, LIPA | KCNN4 4845/4885CYP1A2 4311/4885ALDH1A1 3248/4885 |
| US-20120027796-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, ABCB4, LCAT | KCNN4 4724/4885CYP1A2 4159/4885ALDH1A1 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.